Previous Article | Next Article ![]()
Infection and Immunity, February 1999, p. 708-716, Vol. 67, No. 2
Department of Molecular Genetics and
Microbiology, School of Medicine, State University of New York at
Stony Brook, Stony Brook, New York 11794-5222,1
and
Departments of Medicine and Pharmacology, Columbia University
College of Physicians and Surgeons, New York, New York
100322
Received 21 July 1998/Returned for modification 24 September
1998/Accepted 3 October 1998
Pathogenic Yersinia spp. utilize a plasmid-encoded type
III secretion system to deliver a set of Yop effector proteins into eukaryotic cells. Previous studies have shown that the effector YopJ is
required for Yersinia to cause downregulation of the
mitogen-activated protein (MAP) kinases c-Jun N-terminal kinase (JNK),
p38, and extracellular signal-regulated kinase (ERK) 1 and 2 in
infected macrophages. Here we demonstrate that YopJ is sufficient to
cause downregulation of multiple MAP kinases in eukaryotic cells.
Cellular fractionation experiments confirmed that YopJ is delivered
into the cytoplasmic fraction of macrophages by the type III system. Production of YopJ in COS-1 cells by transfection significantly reduced
(5- to 10-fold) activation of JNK, p38, and ERK in response to several
different stimuli, including serum and tumor necrosis factor alpha. JNK
activation mediated by RacV12, an activated mutant of Rac1, was also
blocked by YopJ in COS-1 cells, indicating that YopJ acts downstream of
this small GTPase to downregulate MAP kinase signaling. Analysis of
transfected COS-1 cells by immunofluorescence microscopy revealed that
YopJ is recruited from the cytoplasmic compartment to the cell
periphery in response to stimuli (e.g., serum) that induce membrane
ruffling. These data indicate that YopJ functions as a "MAP kinase
toxin" to selectively block nuclear responses that are triggered by
Yersinia-host cell interaction.
Three bacterial spp. in the genus
Yersinia cause human disease. Yersinia pestis is
the agent of bubonic plague (9). Yersinia enterocolitica and Yersinia pseudotuberculosis cause
diarrhea, mesenteric lymphadenitis, and septicemia (8, 10).
All three Yersinia spp. carry a 70-kb plasmid, referred to
as pYV (plasmid of Yersinia virulence), that is required for
replication in lymphoid tissues. pYV encodes a type III secretion
pathway that allows extracellular Yersinia to deliver a set
of virulence proteins into the cytoplasmic compartments of host
eukaryotic cells (reviewed in references 11, 15, and
40). The type III pathway is comprised of three
basic components: a ysc-encoded secretion system that delivers proteins to the bacterial surface; a translocation apparatus represented minimally by LcrV, YopB, and YopD; and a set of effector proteins (YopO [YpkA], YopH, YopM, YopJ [YopP], and YopE) (11, 15, 40). The translocated effectors paralyze and kill host cells
and block their ability to produce cytokines (11, 15, 24, 26, 29,
31, 32, 40).
Wild-type strains of Yersinia inhibit production of the
proinflammatory cytokine tumor necrosis factor alpha (TNF- The effector YopJ is required for Yersinia to inhibit
TNF- Although the above data indicate that YopJ is required for
Yersinia to cause downregulation of MAP kinases, it has not
been demonstrated that it is sufficient for this activity. It is
possible that another type III effector protein, in addition to YopJ,
is required for this activity. A second complication is that certain activities attributed to YopJ in macrophages may result from a general
decrease in cell viability due to apoptosis. In order to avoid the
effects of YopJ-mediated cell killing in our studies, we analyzed MAP
kinase downregulation in macrophages prior to the first detectable
signs of apoptosis. The results of infection experiments indicated that
full-length YopJ is translocated into host cells in a YopB-dependent
manner and that it is the only effector encoded by pYV that is required
to cause downregulation of MAP kinases. In addition, we demonstrated by
transfection of fibroblasts that production of YopJ in eukaryotic cells
is sufficient to cause downregulation of JNK, p38, and ERK kinases.
Reagents.
The following oligonucleotides were obtained from
Life Technologies: J3
(5'-GGGAATTCATATGATCGGACCAATATCACAAATAAAT-3') and J9
(5'-AATAAGGATAAATAAATGGAAAGGAATTATCAGTTTCGGTA-3'). FuGENE 6 transfection reagent was purchased from Boehringer Mannheim. Sorbitol and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma.
TNF- Antibodies and immunoblotting conditions.
Phosphospecific
antibodies to p38, JNK, and ERK1 and -2 and standard antibodies to JNK
and ERK1 and -2 were purchased from New England Biolabs. The standard
anti-p38 antibody (Santa Cruz Biotechnology, Inc.) was a gift from J. Galán (State University of New York [SUNY], Stony Brook). The
T7 · Tag antibody (Novagen) was a gift from D. Bar-Sagi (SUNY,
Stony Brook). Immunoblotting with commercial primary antibodies was
done as suggested by the suppliers. The mouse monoclonal antibody M45
(28), which recognizes the 12-amino acid epitope
SRDRLPPFETET, was provided as a hybridoma supernatant by P. Hearing (SUNY, Stony Brook). Immunoblotting with the M45 hybridoma
supernatant was performed at a dilution of 1:500. Anti-mouse
immunoglobulin G and anti-rabbit immunoglobulin G, each conjugated to
horseradish peroxidase (Sigma) were used at a dilution of 1:20,000 or
1:2,000, respectively. Immunoblots were developed with enhanced
chemiluminescence reagents as recommended by the supplier (New England
Nuclear). Films exposed in the linear range were scanned with an LKB
laser densitometer to quantitate relative levels of activated MAP kinases.
Bacterial strains and growth conditions.
The Y. pseudotuberculosis strains used in this study are shown in Table
1. Bacteria were routinely cultivated at
26°C in Luria-Bertani broth or on Luria-Bertani agar plates
containing appropriate antibiotics. For infection assays, overnight
cultures of bacteria were diluted into Luria broth containing 20 mM
sodium oxalate and 20 mM MgCl2 to an optical density at 600 nm of 0.1. Bacteria were grown with shaking at 26°C for 1 h and
then shifted to 37°C for 2 to 3 h to induce maximal Yop
expression. Where indicated, IPTG
(isopropyl-
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
YopJ of Yersinia spp. Is Sufficient To Cause
Downregulation of Multiple Mitogen-Activated Protein Kinases in
Eukaryotic Cells

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
) in vivo (27) and in cultured macrophages (2, 5, 29, 34).
Wild-type strains of Yersinia also downregulate the
mitogen-activated protein (MAP) kinases c-Jun N-terminal kinase (JNK),
p38, and extracellular signal-regulated kinase (ERK) in macrophages
(5, 29, 34). As MAP kinases play an important role in the
regulation of proinflammatory cytokine biosynthesis (20, 22, 25,
30, 41, 45), this is likely to represent the mechanism used by
these bacteria to inhibit cytokine production (5, 29, 34).
production and cause downregulation of MAP kinases in
macrophages (5, 29). The ability of Yersinia to
kill macrophages by apoptosis is also dependent upon YopJ (24,
26). YopJ is a 30-kDa protein of unknown activity
(39). The translocation factor YopB is required for
suppression of TNF-
production (5, 29), indicating that YopJ (and possibly other essential effectors) must be delivered into
cells for this repressive activity to be expressed. Consistent with the
idea that YopJ is translocated into host cells, a cyclase reporter
protein linked to the first 99 residues of YopJ can be internalized
into macrophages at low but detectable levels in a YopB-dependent
manner (36). Furthermore, AvrA, a YopJ-related protein found
in Salmonella, is translocated into host cells via the
invasion-associated type III pathway (17).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
was purchased from Calbiochem.
-D-thiogalactopyranoside) was added (100 µM
final concentration) to the growth media at the time of the temperature shift to 37°C in order to induce expression of yopJM45.
Bacteria were pelleted by microcentrifugation, resuspended to an
optical density at 600 nm of 1.0 in Hanks balanced salt solution, and used to infect macrophages at a multiplicity of infection of 100.
TABLE 1.
Strains and plasmids
Construction of yop mutants. Mutants were constructed by allelic recombination as described previously (29). YP19 (yopEHB) was derived from YP17 (yopEH) by deleting nucleotides 496 to 774 of yopB with the suicide plasmid pJB4 (29). YP27 (yopEHJ) and YP29 (yopEHJB) were derived from YP17 and YP19, respectively, by deleting nucleotides 1 to 795 of yopJ with the suicide plasmid pLP13 (29). Virulence plasmid DNA from YP27 and YP29 was purified and electroporated into the plasmid-cured strain IP2666, resulting in IP27 and IP29, respectively.
Construction of plasmids. Plasmids are listed in Table 1. A DNA fragment containing yopH fused to a carboxy-terminal M45 epitope (yopHM45) was inserted into the multicloning site of pGEX-2T, resulting in pLP15. In pLP15, yopHM45 is flanked by a 5' NdeI and 3' EcoRI site, and an XmaI site is present at the point of fusion between the yopH and M45 sequences. pLP16 was constructed by replacing the yopH sequence in pLP15 with an NdeI-XmaI fragment containing the yopJ coding region. The yopJ coding region was obtained by PCR amplification, by using primers J3 and J9, followed by digestion with NdeI and XmaI. The structure of the yopJM45 gene in pLP16 was verified by sequencing. To construct pYOPHM45, the yopHM45 gene was inserted into the multicloning site of pMMB67HE (14), placing it under the control of the ptac promoter. pLP17 was constructed by replacing the yopJM45 sequence in pYOPHM45 with an NdeI-EcoRI fragment containing the yopJM45 coding region. pSFFV (15a) was derived from pCMV3Rluc (12) by replacing the cytomegalovirus promoter with the spleen focus-forming virus (SFFV) promoter (provided by Michel Nussenswieg). The yopJM45 gene was inserted between the ApaI and NotI sites of pSFFV, yielding pLP20.
Analysis of MAP kinase downregulation in macrophages. J774A.1 murine macrophage-like cells were grown as described previously (29). Twenty-four hours prior to infection, 2 × 106 macrophages in 3 ml of Dulbecco modified Eagle medium containing 10% fetal bovine serum (DMEM-10% FBS) (GIBCO BRL) were seeded into 60-mm-diameter tissue culture dishes. Fifteen minutes prior to infection, the macrophages were overlaid with 3 ml of fresh DMEM-10%FBS. A total of 2 × 108 bacteria grown as described above were then added to each well. After 15 or 45 min, the cells were washed once with ice-cold phosphate-buffered saline (PBS) containing 1 mM Na3VO4 and 10 mM NaF. Washed cells were lysed for 15 min on ice with 0.5 ml of modified radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1 mM Na3VO4, 10 mM NaF). Lysates were clarified by centrifugation for 15 min at 4°C at 12,000 × g. Protein concentrations were determined by using the Bio-Rad protein assay. Samples containing approximately 20 µg of protein were boiled in Laemmli sample buffer (1× Laemmli sample buffer containing 10 mM dithiothreitol), separated on SDS-10% polyacrylamide gels, and transferred to nitrocellulose membranes. Membranes were probed with phosphospecific antibodies or standard antibodies according to the manufacturers' instructions.
Detergent solubility assay. Macrophages were infected with bacteria as described above. Where indicated, the tissue culture medium was supplemented with IPTG (100 µM final concentration) to induce expression of yopJM45. Two hours postinfection, the dishes were washed three times in ice-cold PBS containing 1 mM Na3VO4 and 10 mM NaF. To each dish 0.5 ml of cold 1% Triton X-100 buffer (10 mM Tris [pH 7.6], 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM Na3VO4, 10 mM NaF, 200 µM AEBSF [aminoethylbenzenesulfonyl fluoride], 20 µM leupeptin, and 1 µM pepstatin) was added, and the dishes were incubated for 15 min on ice with occasional rocking. Infected cells were scraped with the lysis buffer into microcentrifuge tubes and centrifuged 10 min at 12,000 × g at 4°C. Supernatants (soluble fractions) were transferred to new tubes, and protein concentrations were determined by using the Bio-Rad protein assay. Soluble fractions were diluted to 0.8 µg per µl in Laemmli sample buffer and boiled. Pellets (insoluble fractions) were carefully washed in lysis buffer, resuspended in 100 µl of Laemmli sample buffer, and boiled. A volume of 25 µl of each soluble fraction (approximately 2% of the total) and 10 µl of each insoluble fraction (10% of the total) were separated on SDS-10% polyacrylamide gels and transferred to a nitrocellulose membrane. Immunoblots were developed with the M45 antibody. In mock infection experiments, 2 × 108 bacteria were inoculated into 60-mm-diameter dishes containing 3 ml of DMEM-10%FBS. Incubations, extractions, and immunoblots were carried out exactly as described above, with the exception that 10 µl of each soluble protein sample (approximately 2% of the total) was analyzed.
Analysis of MAP kinase downregulation in COS-1 cells.
COS-1
cells were passaged in DMEM containing 5% FBS (DMEM-5%FBS).
Twenty-four hours prior to transfection, 105 COS-1 cells in
2 ml of DMEM-5%FBS were seeded into the wells of a 6-well dish. COS-1
cells were transfected with 1 µg of pSFFV or pLP20 mixed with 3 µl
of the FuGENE 6 transfection reagent according to the manufacturer's
instructions. Twenty-four hours after transfection, the medium was
replaced with serum-free DMEM. After 16 h, the medium overlaying
the transfected cells was removed, and the cells were incubated for 30 min with DMEM alone or with DMEM supplemented with 10% FBS, 0.4 M
sorbitol, 50 ng of TNF-
per ml, or 100 ng of PMA per ml. COS-1 cells
were washed with ice-cold PBS containing 1 mM
Na3VO4 and 10 mM NaF and lysed in 200 µl of
modified RIPA buffer, as described above. Protein concentrations of
soluble lysates were determined by using the Bio-Rad protein assay.
Samples of the lysates containing approximately 15 µg of protein were
separated on SDS-10% polyacrylamide gels and transferred to
nitrocellulose membranes. Membranes were developed with either the M45
antibody, the phosphospecific MAP kinase antibodies, or the standard
MAP kinase antibodies.
Immunofluorescence microscopy. Twenty-four hours prior to transfection, 104 COS-1 cells in 1 ml of DMEM-5%FBS were seeded into the wells of a 24-well dish containing glass coverslips. COS-1 cells were transfected with 0.5 µg of pLP20 and 1.5 µl of FuGENE 6 transfection reagent according to the manufacturer's instructions. Cells were serum starved and stimulated as described above. Thirty minutes after stimulation, the transfected cells were processed for immunofluorescence as described previously (3) by using the M45 antibody (1:100 dilution) as the primary antibody and anti-mouse fluorescein isothiocyanate conjugate (1:500 dilution) as the secondary antibody. Images were captured with a confocal laser microscope as described previously (3).
| |
RESULTS |
|---|
|
|
|---|
YopJ is required for downregulation of ERK at early infection times. Previous results indicated that YopJ is required for Y. pseudotuberculosis to cause downregulation of JNK and p38 in macrophages (29). In addition, Boland and Cornelis (5) found that YopJ is required for inhibition of ERK activity in macrophages infected with Y. enterocolitica. However, ERK kinase activity was measured 3.5 h postinfection (5), at which time up to 80% of infected macrophages may be killed in a YopJ-dependent fashion (24, 26, 35). The results of a time course infection experiment using macrophages indicated that JNK is completely downregulated by Y. pseudotuberculosis within 45 min of infection (data not shown), which is prior to the first detectable signs of apoptosis (24, 26, 35). We analyzed ERK activation at 15 and 45 min postinfection in order to rule out an indirect effect of macrophage death on ERK kinase activity. J774A.1 macrophages were infected with a wild-type serogroup III strain (YP126), an isogenic yopJ mutant (YP26), or an isogenic ysc mutant (YP71) defective in the type III pathway (Table 1). Within 15 or 45 min of infection, the macrophages were lysed and samples of the lysates were analyzed by immunoblotting with an antibody that specifically recognizes the activated form of the MAP kinase (phosphospecific antibody). Initially, the blots were developed with a phosphospecific JNK antibody as a control. As shown in Fig. 1A, little or no activated JNK was detected in uninfected macrophages (lane 1). The two major isoforms of JNK (p54 JNK and p46 JNK) were activated at 15 min postinfection when macrophages were infected with either the wild-type strain, the ysc mutant, or the yopJ mutant (Fig. 1A, lanes 2, 4, and 6, respectively). At 45 min postinfection, JNK was downregulated in macrophages infected with the wild-type strain (Fig. 1A, lane 3), but it remained activated in macrophages infected with the ysc or yopJ mutants (lanes 5 and 7, respectively). A control immunoblot probed with a standard JNK antibody demonstrated equal loading of JNK in each lane (Fig. 1B). Thus, as shown previously, YopJ is required for Y. pseudotuberculosis to downregulate JNK at 45 min postinfection (29). Identical results have been reported for p38 (29).
|
YopJ is delivered into the cytoplasmic fraction of
macrophages in a YopB-dependent process.
A fusion protein
consisting of the first 99 residues of YopJ linked to a
cyclase reporter protein can be translocated into the cytosol of
macrophages in a YopB-dependent manner (36). To extend these
results to the native YopJ protein, we attempted to detect
intracellular delivery of YopJ into infected host cells by using
immunofluorescence microscopy. For this experiment, we fused the M45
epitope onto the 3' end of the YopJ open reading frame (see Materials
and Methods). The yopJM45 gene was inserted into a multicopy
expression vector under the control of the ptac promoter,
and the resulting plasmid was introduced into a Y. pseudotuberculosis yopEHJ mutant (IP27) (Table 1). IP27 is derived
from the serogroup III strain IP2666. We have found that this strain is
able to translocate higher levels of Yop proteins into host cells than
the YPIII strain (data not shown). As a positive control, we also fused
the M45 epitope onto the carboxy-terminal end of YopH and expressed
this protein in the same genetic background. Macrophages or HeLa cells were infected for 2 h with these strains, stained with the M45 antibody, and examined by immunofluorescence microscopy. Although YopHM45 could be readily detected in the cytoplasmic compartments of
the infected cells, YopJM45 could not be detected inside host cells in
the presence or absence of IPTG induction (data not shown). The YopJM45
protein had wild-type activity, as determined by its ability to
complement a yopJ mutant in a TNF-
suppression assay (data not shown). From these results, we concluded that YopJ is translocated at levels that are too low to allow detection by standard
immunofluorescence microscopic techniques.
|
YopJ is sufficient to cause downregulation of JNK, p38, and ERK in
eukaryotic cells.
To determine if YopJ is sufficient to cause
downregulation of JNK, p38, and ERK in host cells, we inserted
yopJM45 into a eukaryotic expression vector under the
control of the SFFV promoter and introduced the resulting plasmid
(pLP20) into cultured mammalian cells by a highly efficient
transfection procedure (see Materials and Methods). Since macrophage
cell lines are difficult to transfect, we initially introduced pLP20
into the highly transfectable kidney cell line COS-1. Thirty hours
posttransfection the cells were examined by immunofluorescence
microscopy after staining with the M45 antibody. Approximately 90% of
the cells transfected with pLP20 were stained brightly with the M45
antibody (see Fig. 6), while no specific staining was observed in cells
transfected with the empty vector (data not shown). To determine if
expression of YopJM45 in COS-1 cells induced apoptosis, transfected
cells were simultaneously stained with the M45 antibody and DAPI
(4',6-diamidino-2-phenylindole) to label the nuclei. We observed no
fragmentation of nuclei (an indicator of apoptosis) in cells producing
YopJM45 (data not shown). To determine if YopJ is sufficient to cause
downregulation of MAP kinases in COS-1 cells, we treated transfected
cells with serum, sorbitol, TNF-
, or PMA. These stimuli have been
shown to activate JNK, p38, and ERK in various cell types (20, 25, 30, 45). Lipopolysaccharide, which is a potent activator of MAP
kinases in macrophages (41), was not used as a stimulus in
this application, since lipopolysaccharide treatment of COS-1 cells
does not cause significant activation of MAP kinases (15a). Serum-starved COS-1 cells transfected with the empty vector or pLP20
were stimulated with these agonists for 30 min and then lysed. Lysates
were first analyzed by immunoblotting with the M45 antibody to verify
the equal expression of YopJM45 under all conditions (Fig.
3A). Lysates were then analyzed by
immunoblotting with the phosphospecific or standard JNK antibody (Fig.
3B and C, respectively). Unstimulated COS-1 cells transfected with
vector alone contained low levels of active JNK (Fig. 3B, lane 1). The baseline level of JNK activation was reduced approximately 10-fold in
cells transfected with pLP20 (Fig. 3B, lane 2). JNK activation increased significantly upon the exposure of vector-transfected cells
to serum, sorbitol, TNF-
, or PMA (Fig. 3B, lanes 3, 5, 7, and 9).
JNK activation in response to serum, sorbitol, TNF-
, or PMA was
approximately 10-fold lower in cells transfected with pLP20 (Fig. 3B,
lanes 4, 6, 8, and 10). Relative levels of active p54 JNK in cells
treated with serum or TNF-
were quantitated by densitometry and are
shown in Fig. 4A.
|
|
are
plotted in Fig. 4B. There was a fivefold decrease in the level of
active ERK in cells transfected with pLP20 compared to cells
transfected with the empty vector (Fig. 3F and 4B). These results
indicated that YopJ is sufficient to cause downregulation of the JNK,
p38, and ERK kinases in host cells exposed to several different
activators of MAP kinase pathways.
YopJ acts downstream of Rac activation to downregulate JNK. The small GTPase Rac1 acts as an upstream activator of the JNK kinase cascade (20, 25, 30, 45). To determine if YopJ acts at a level above or below that of Rac to downregulate JNK activity, we introduced a constitutively activated mutant of Rac1 (RacV12) into COS-1 cells by transfection. Production of RacV12 was confirmed by immunoblotting with an antibody specific for the T7 epitope fused to RacV12 (Fig. 5B, lanes 3 and 4). Figure 5C shows that production of RacV12 in serum-starved COS-1 cells caused a significant increase in JNK activation (compare lanes 1 and 3). In contrast, activated JNK was not detected when YopJM45 was produced together with RacV12 in COS-1 cells (Fig. 5C, lane 4). These results indicate that YopJ acts at a step below Rac activation to cause downregulation of the JNK kinase cascade.
|
YopJ concentrates at the periphery of host cells in response to
stimuli that induce membrane ruffling.
To examine the localization
of YopJ within host cells, COS-1 cells were transfected with pLP20 and
serum starved as before. The transfected cells were processed for
immunofluorescence microscopy by using the M45 antibody and anti-mouse
fluorescein isothiocyanate antibody as the secondary antibody. The
cells were then examined by confocal microscopy. Figure
6A shows a single representative image of
a section through two serum-starved transfected cells. Under these
conditions, YopJM45 localized throughout cytoplasmic compartments of
the transfected cells. When the transfected cells were stimulated with
serum for 30 min and then analyzed as before, strong staining was
detected at the cell periphery (Fig. 6B). No peripheral staining was
seen in vector-transfected cells following exposure to serum (data not
shown). A similar peripheral staining of YopJM45 at the cell boundary
was observed when cells were treated with PMA for 30 min, while no such
staining was seen in cells stimulated with sorbitol or TNF-
(data
not shown). As serum and PMA are known to stimulate membrane ruffling
as well as MAP kinase activation (for a review see reference
16), the peripheral staining observed in the
presence of these agonists may reflect the recruitment of YopJ to
membrane ruffles.
|
| |
DISCUSSION |
|---|
|
|
|---|
The goal of this study was to determine if Yersinia YopJ is sufficient to cause downregulation of MAP kinases in host cells. Initially, we asked if other known Yops encoded by pYV are required for Y. pseudotuberculosis to downregulate MAP kinases in macrophages. We analyzed strains defective in multiple yop genes and found that the effectors YopH, YopE, YopM, and YopO and the translocation regulator YopK were dispensable for this activity, while YopJ was required. These results are consistent with those of Boland and Cornelis (5), who showed that YopH, YopE, YopM, YopO, and YopK were dispensable for Y. enterocolitica to inhibit activation of p38 and ERK in macrophages. An important difference between our study and that of Boland and Cornelis is that we analyzed MAP kinase downregulation at 45 min postinfection, prior to the first detectable signs of apoptosis, while they measured MAP kinase activation at 3.5 h, at which time a significant fraction of macrophages are dead. Thus, our data rule out the possibility that YopJ-mediated inhibition of ERK kinase in macrophages by Yersinia is an indirect effect of cell death.
We next addressed the issue of whether full-length YopJ is translocated
into host cells via the type III pathway. Sarker et al. (36)
have shown that the first 99 residues of YopJ can direct the
translocation of a cyclase fusion protein into macrophages in a
YopB-dependent manner, although at levels approximately fourfold lower than a YopE-cyclase fusion protein. We were unable to detect the
intracellular delivery of native YopJ into infected host cells by
standard immunofluorescence microscopy techniques, apparently because
of the low level at which this protein is translocated. Using a
detergent solubility assay that is sensitive and discriminates between
bacteria-associated and translocated Yops, we obtained results
consistent with the idea that full-length YopJ is translocated into
macrophages in a YopB-dependent process. These results are consistent
with the demonstration that YopB is required for Yersinia to
inhibit TNF-
production (5, 29).
As all available evidence indicated that YopJ is translocated into host
cells via the plasmid-encoded type III pathway, we next addressed the
question of whether YopJ is sufficient to cause downregulation of MAP
kinases. For this purpose, the yopJ gene was inserted into a
eukaryotic expression vector and transfected into COS-1 cells. Using a
highly efficient transfection protocol we were able to obtain
transfection efficiencies greater than 90%. Expression of YopJ in
COS-1 cells did not appear to induce apoptosis based on DAPI staining
of nuclei. This was expected since epithelial cell lines do not undergo
apoptosis in response to infection with Yersinia unless they
are simultaneously exposed to TNF-
(33). We used
immunoblotting to monitor the levels of active JNK, p38, and ERK in
transfected COS-1 cells in the presence or absence of several different
activators of MAP kinase pathways. Expression of YopJ in COS-1 cells
caused a 10-fold reduction in the baseline level of active JNK or p38
in these cells, as well as a 10-fold reduction in JNK or p38 activation
following stimulation. Similar results were obtained in the case of
ERK, although the magnitude of YopJ-mediated kinase downregulation appeared to be lower, approximately fivefold. Upon stimulation of
transfected COS-1 cells with serum or PMA, which are known to induce
membrane ruffling as well as activate MAP kinases, we observed a
redistribution of YopJ from the cytoplasmic compartment to the cell
periphery. This may indicate that YopJ interacts with a component of
MAP kinase signaling cascades that is recruited to membrane ruffles.
Expression of YopJ did not appear to interfere with the formation of
membrane ruffles in COS-1 cells, based on preliminary studies in which
serum-stimulated cells transfected with pLP20 were simultaneously
stained with the M45 antibody and phalloidin to label F-actin-rich
membrane ruffles (data not shown). These results show that YopJ is
sufficient to cause downregulation of ERK, p38, and JNK kinases in
eukaryotic cells. Furthermore, our data suggest that YopJ selectively
blocks the nuclear responses and not the cytoskeletal rearrangements
that can accompany activation of MAP kinase cascades.
One major issue that remains to be addressed is the mechanism by which YopJ causes downregulation of MAP kinases. It is generally thought that the ERK kinase signaling cascade is distinct and separate from the signaling pathway leading to JNK or p38 (20, 25, 30, 45). Stimulation of ERK proceeds via the sequential activation of Ras, Raf-1, and MEK1. Stimulation of JNK and p38 proceeds by the sequential activation of Rac and/or Cdc42hs, PAK, a MAP kinase kinase kinase (MEKK), and a MAP kinase kinase (MKK). Thus, there appears to be no common upstream signaling intermediate that is required for activation of ERK, p38, and JNK kinases. As a consequence, YopJ may need to interact with multiple, possibly functionally related targets to cause downregulation of all three kinases. As an initial step toward defining the level at which YopJ acts to downregulate MAP kinase cascades, we introduced the constitutively activated RacV12 protein into COS-1 cells. We found that YopJ was able to downregulate JNK activation mediated by RacV12. This result argues that YopJ acts below the level of GTPase activation to block MAP kinase signaling pathways. Ruckdeschel et al. (34) have reported that wild-type Y. enterocolitica impairs activation of Raf-1. If this repressive effect is in fact due to YopJ, it would suggest that downregulation occurs at or above the level of a MAP kinase kinase kinase. Recently, Frost et al. (13) presented evidence for a "cross-cascade" interaction between the ERK and JNK signaling pathways. This appears to involve phosphorylation of MEK1 by PAK on serine 298, a site important for binding of Raf-1 to MEK1 (13). This cross-cascade interaction is not required for activation of ERK, but it can increase the duration and amplitude of the response (13). It is possible that YopJ acts at a step in the JNK and p38 signaling pathways that is at or above the point at which this cross-cascade regulation occurs. According to this model, YopJ would be expected to reduce, but not completely block, activation of the ERK kinase. We have observed that ERK activation is less sensitive to YopJ downregulation than JNK and p38, a finding which is consistent with this model.
Several groups have reported that Yersinia induces apoptosis
in macrophages (24, 26, 35) and that this cell death
requires YopJ (24, 26). In addition, Ruckdeschel et al.
(33) have shown that Y. enterocolitica impairs
activation of the transcription factor NF-
B in macrophages. NF-
B
plays an essential role in preventing apoptosis in response to
treatment of eukaryotic cells with several different stimuli, including
TNF-
(1, 43, 44). Thus, Yersinia may induce
apoptosis in macrophages by antagonizing NF-
B rather than by
activating an apoptotic program. While this paper was in preparation,
Schesser et al. reported that YopJ is required for Y. pseudotuberculosis to inhibit activation of NF-
B in HeLa cells
(37). In addition, they identified a region in YopJ that
shows similarity to a segment of eukaryotic Src homology 2 domains
(37). These results suggest that YopJ directly downregulates the signaling pathway leading to activation of NF-
B. How this occurs
is at present unclear, although recent studies have suggested that MEKK
is involved in the pathway leading to NF-
B activation (18, 21,
23). Therefore, it is possible that all of the biological
activities attributed to YopJ are a direct consequence of its ability
to inhibit upstream components of MAP kinase cascades.
| |
ACKNOWLEDGMENTS |
|---|
We thank J. Galán, D. Black, and L. Montagna for comments on the manuscript and D. Bar-Sagi and P. Hearing for providing reagents.
This research was supported by a grant from the National Institutes of Health (AI35175). L.E.P. was supported by a National Institutes of Health training grant (2T32CAO9176). A.R.P. was supported by the Conselho Nacional Para O Desenvolvimento Cientifico E Technológico, Brazil. J.B.B. is a PEW scholar in the biomedical sciences.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Molecular Genetics and Microbiology, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794-5222. Phone: (516) 632-8782. Fax: (516) 632-9797. E-mail: bliska{at}asterix.bio.sunysb.edu.
Present address: Yale University School of Medicine, Boyer Center
for Molecular Medicine, Section of Microbial Pathogenesis, New Haven,
CT 06536-0812.
Editor: P. J. Sansonetti
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Beg, A. A., and D. Baltimore.
1996.
An essential role for NF- B in preventing TNF -induced cell death.
Science
274:782-784 |
| 2. | Beuscher, H. U., F. Rödel, A. Forsberg, and M. Röllinghoff. 1995. Bacterial evasion of host immune defense: Yersinia enterocolitica encodes a suppressor for tumor necrosis factor alpha expression. Infect. Immun. 63:1270-1277[Abstract]. |
| 3. | Black, D. S., and J. B. Bliska. 1997. Identification of p130Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J. 16:2730-2744[Medline]. |
| 4. |
Bliska, J. B.,
K. Guan,
J. E. Dixon, and S. Falkow.
1991.
Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant.
Proc. Natl. Acad. Sci. USA
88:1187-1191 |
| 5. |
Boland, A., and G. R. Cornelis.
1998.
Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection.
Infect. Immun.
66:1878-1884 |
| 6. |
Bölin, I.,
L. Norlander, and H. Wolf-Watz.
1982.
Temperature-inducible outer membrane protein of Yersinia pseudotuberculosis and Yersinia enterocolitica is associated with the virulence plasmid.
Infect. Immun.
37:506-512 |
| 7. |
Bölin, I., and H. Wolf-Watz.
1984.
Molecular cloning of the temperature-inducible outer membrane protein 1 of Yersinia pseudotuberculosis.
Infect. Immun.
43:72-78 |
| 8. | Bottone, E. J. 1997. Yersinia enterocolitica: the charisma continues. Clin. Microbiol. Rev. 10:257-276[Abstract]. |
| 9. |
Brubaker, R. R.
1991.
Factors promoting acute and chronic diseases caused by yersiniae.
Clin. Microbiol. Rev.
4:309-324 |
| 10. | Cornelis, G., Y. Laroche, G. Balligand, M. P. Sory, and G. Wauters. 1987. Yersinia enterocolitica, a primary model for bacterial invasiveness. Rev. Infect. Dis. 9:64-87[Medline]. |
| 11. | Cornelis, G. R., and H. Wolf-Watz. 1997. The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol. Microbiol. 23:861-867[Medline]. |
| 12. |
Cox, D.,
P. Chang,
Q. Zhang,
P. G. Reddy,
G. M. Bokoch, and S. Greenberg.
1997.
Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes.
J. Exp. Med.
186:1487-1494 |
| 13. | Frost, J. A., H. Steen, P. Shapiro, T. Lewis, N. Ahn, P. E. Shaw, and M. H. Cobb. 1997. Cross-cascade activation of ERKs and ternary complex factors by Rho family members. EMBO J. 16:6426-6438[Medline]. |
| 14. | Furste, J. P., W. Pansegrau, R. Frank, H. Blocker, P. Scholz, M. Bagdasarian, and E. Lanka. 1986. Molecular cloning of the plasmid RP4 primase region in a multi-host range tacP expression vector. Gene 48:119-131[Medline]. |
| 15. | Galán, J. E., and J. B. Bliska. 1996. Cross-talk between bacterial pathogens and their host cells. Annu. Rev. Cell Dev. Biol. 12:221-255[Medline]. |
| 15a. | Greenberg, S. Unpublished data. |
| 16. |
Hall, A.
1998.
Rho GTPases and the actin cytoskeleton.
Science
279:509-514 |
| 17. |
Hardt, W.-D., and J. E. Galán.
1997.
A secreted Salmonella protein with homology to an avirulence determinant of plant pathogenic bacteria.
Proc. Natl. Acad. Sci. USA
94:9887-9892 |
| 18. |
Hirano, M.,
S. Osada,
T. Aoki,
S. Hirai,
M. Hosaka,
J. Inoue, and S. Ohno.
1996.
MEK kinase is involved in tumor necrosis factor -induced NF- B activation and degradation of I B- .
J. Biol. Chem.
271:13234-13238 |
| 19. | Holmstrom, A., J. Pettersson, R. Rosqvist, S. Hakansson, F. Tafazoli, M. Fallman, K.-E. Magnusson, H. Wolf-Watz, and A. Forsberg. 1997. YopK of Yersinia pseudotuberculosis controls translocation of Yop effectors across the eukaryotic cell membrane. Mol. Microbiol. 24:73-91[Medline]. |
| 20. | Kyriakis, J. M., and J. Avruch. 1996. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18:567-577[Medline]. |
| 21. |
Lee, F. S.,
J. Hagler,
Z. J. Chen, and T. Maniatis.
1997.
Activation of the I B kinase complex by MEKK1, a kinase of the JNK pathway.
Cell
88:213-222[Medline].
|
| 22. | Lee, J. C., and P. R. Young. 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 59:152-157[Abstract]. |
| 23. |
Meyer, C. F.,
X. Wang,
C. Chang,
D. Templeton, and T.-H. Tan.
1996.
Interaction between c-Rel and the mitogen-activated protein kinase kinase 1 signaling cascade in mediating B enhancer activation.
J. Biol. Chem.
271:8971-8976 |
| 24. |
Mills, S. D.,
A. Boland,
M.-P. Sory,
P. van der Smissen,
C. Kerbourch,
B. B. Finlay, and G. R. Cornelis.
1997.
Yersinia enterocolitica induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein.
Proc. Natl. Acad. Sci. USA
94:12638-12643 |
| 25. | Minden, A., and M. Karin. 1997. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1333:F85-F104[Medline]. |
| 26. |
Monack, D. M.,
J. Mecsas,
N. Ghori, and S. Falkow.
1997.
Yersinia signals macrophages to undergo apoptosis and YopJ is necessary for this cell death.
Proc. Natl. Acad. Sci. USA
94:10385-10390 |
| 27. |
Nakajima, R., and R. R. Brubaker.
1993.
Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.
Infect. Immun.
61:23-31 |
| 28. |
Obert, S.,
R. J. O'Connor,
S. Schmid, and P. Hearing.
1994.
The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex.
Mol. Cell. Biol.
14:1333-1346 |
| 29. |
Palmer, L. E.,
S. Hobbie,
J. E. Galan, and J. B. Bliska.
1998.
YopJ of Yersinia pseudotuberculosis is required for the inhibition of macrophage TNF production and the downregulation of the MAP kinases p38 and JNK.
Mol. Microbiol.
27:953-965[Medline].
|
| 30. | Robinson, M. J., and M. H. Cobb. 1997. Mitogen-activated protein kinase cascades. Curr. Opin. Cell Biol. 9:180-186[Medline]. |
| 31. |
Rosqvist, R.,
I. Bolin, and H. Wolf-Watz.
1988.
Inhibition of phagocytosis in Yersinia pseudotuberculosis: a virulence plasmid-encoded ability involving the Yop2b protein.
Infect. Immun.
56:2139-2143 |
| 32. | Rosqvist, R., A. Forsberg, M. Rimpilainen, T. Bergman, and H. Wolf-Watz. 1990. The cytotoxic protein YopE of Yersinia obstructs the primary host defence. Mol. Microbiol. 4:657-667[Medline]. |
| 33. |
Ruckdeschel, K.,
S. Harb,
A. Roggenkamp,
M. Hornef,
R. Zumbihl,
S. Kohler,
J. Heesemann, and B. Rouot.
1998.
Yersinia enterocolitica impairs activation of transcription factor NF- B: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor production.
J. Exp. Med.
187:1069-1079 |
| 34. |
Ruckdeschel, K.,
J. Machold,
A. Roggenkamp,
S. Schubert,
J. Pierre,
R. Zumbihl,
J.-P. Liautard,
J. Heesemann, and B. Rouot.
1997.
Yersinia enterocolitica promotes deactivation of macrophage mitogen-activated protein kinases extracellular signal-regulated kinase-1/2, p38, and c-Jun NH2-terminal kinase.
J. Biol. Chem.
272:15920-15927 |
| 35. | Ruckdeschel, K., A. Roggenkamp, V. Lafont, P. Mangeat, J. Heesemann, and B. Rouot. 1997. Interaction of Yersinia enterocolitica with macrophages leads to macrophage cell death through apoptosis. Infect. Immun. 65:4813-4821[Abstract]. |
| 36. |
Sarker, M.,
M.-P. Sory,
A. P. Boyd,
M. Iriarte, and G. R. Cornelis.
1998.
LcrG is required for efficient translocation of Yersinia Yop effector proteins into eukaryotic cells.
Infect. Immun.
66:2976-2979 |
| 37. |
Schesser, K.,
A.-K. Spiik,
J.-M. Dukuzumuremyi,
M. F. Neurath,
S. Pettersson, and H. Wolf-Watz.
1998.
The yopJ locus is required for Yersinia-mediated inhibition of NF- B activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is required for its repressive activity.
Mol. Microbiol.
28:1067-1080[Medline].
|
| 38. | Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31-40[Medline]. |
| 39. |
Straley, S. C., and W. S. Bowmer.
1986.
Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins.
Infect. Immun.
51:445-454 |
| 40. |
Straley, S. C.,
E. Skrzypek,
G. V. Plano, and J. B. Bliska.
1993.
Yops of Yersinia spp. pathogenic for humans.
Infect. Immun.
61:3105-3110 |
| 41. | Ulevitch, R. J., and P. S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:437-457[Medline]. |
| 42. | Van Aelst, L., T. Joneson, and D. Bar-Sagi. 1996. Identification of a novel Rac1-interacting protein involved in membrane ruffling. EMBO J. 15:3778-3786[Medline]. |
| 43. |
Van Antwerp, D. J.,
S. J. Martin,
T. Kafri,
D. R. Green, and I. M. Verma.
1996.
Suppression of TNF -induced apoptosis by NF- B.
Science
274:787-789 |
| 44. |
Wang, C.-U.,
M. W. Mayo, and A. S. Baldwin, Jr.
1996.
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF- B.
Science
274:784-787 |
| 45. | Witmarsh, A. J., and R. J. Davis. 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:589-607[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»